Catalyst Wire Dossier Catalyst Wire Dossier

Siltuximab

siltuximab · Janssen Biotech, Inc.
Drug timelines are a Plus or Pro feature.

17 regulatory and trial events tracked for Siltuximab, covering 2014-05-14 to 2026-06-03. Get the full timeline:

Most recent: Clinical Trial Results: Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy [Phase 2]

See pricing